Amicus Therapeutics (FOLD) Expected to Announce Quarterly Earnings on Wednesday

Amicus Therapeutics (NASDAQ:FOLD) is expected to release its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect Amicus Therapeutics to post earnings of $0.13 per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 12:30 PM ET.

Amicus Therapeutics Price Performance

Shares of FOLD opened at $14.31 on Tuesday. The stock has a market cap of $4.49 billion, a P/E ratio of -357.66 and a beta of 0.38. Amicus Therapeutics has a 1 year low of $5.51 and a 1 year high of $14.38. The stock’s 50-day moving average price is $13.67 and its two-hundred day moving average price is $10.23. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70.

Insider Transactions at Amicus Therapeutics

In other news, insider Jeff Castelli sold 76,158 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $10.16, for a total value of $773,765.28. Following the sale, the insider owned 439,318 shares of the company’s stock, valued at $4,463,470.88. The trade was a 14.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 77,926 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $10.86, for a total transaction of $846,276.36. Following the completion of the transaction, the chief executive officer directly owned 1,129,782 shares of the company’s stock, valued at approximately $12,269,432.52. This trade represents a 6.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 394,807 shares of company stock worth $4,486,385. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Van ECK Associates Corp grew its stake in shares of Amicus Therapeutics by 35.1% in the third quarter. Van ECK Associates Corp now owns 5,638 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,466 shares in the last quarter. Xponance LLC lifted its stake in Amicus Therapeutics by 7.5% in the 4th quarter. Xponance LLC now owns 23,532 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 1,643 shares during the last quarter. Parallel Advisors LLC grew its holdings in Amicus Therapeutics by 40.2% during the third quarter. Parallel Advisors LLC now owns 5,756 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,649 shares during the period. Gotham Asset Management LLC grew its holdings in Amicus Therapeutics by 1.5% during the third quarter. Gotham Asset Management LLC now owns 138,523 shares of the biopharmaceutical company’s stock worth $1,092,000 after purchasing an additional 1,987 shares during the period. Finally, CANADA LIFE ASSURANCE Co increased its position in Amicus Therapeutics by 2.8% during the second quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 2,263 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages recently issued reports on FOLD. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Monday, December 29th. TD Cowen cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price target on the stock. in a research report on Monday, December 22nd. Needham & Company LLC cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 19th. The Goldman Sachs Group raised their target price on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Finally, Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $15.55.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.